Mark Moshiyakhov, MD
Cardiovascular Disease · Browns Mills, NJNPI 1538293576
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (35.5%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abiomed at 53.5% of the total. Reporting peaked in 2019 at $7,296 and has fallen 77.5% since, to $1,642 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $154.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$11K
- Abbott$5K
- Edwards Lifesciences$2K
- Livanova USA, Inc.$768
- Biotronik Inc.$674
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$658
- plus $2K from 11 others
What the payments were for
- Speaking & faculty fees$6,50030%
- Travel & lodging$7,36034%
- Food & beverage$7,61935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 44 | $11,497 |
| Abbott | 37 | $4,545 |
| Edwards Lifesciences | 10 | $1,576 |
| Livanova USA, Inc. | 1 | $768 |
| Biotronik Inc. | 18 | $674 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $658 |
| Kestra Medical Technology Services, Inc. | 5 | $416 |
| AstraZeneca | 4 | $368 |
| Boston Scientific | 3 | $307 |
| Medtronic | 1 | $213 |
| Johnson & Johnson | 1 | $131 |
| Atricure, Inc. | 1 | $120 |
| Inari Medical, Inc. | 1 | $78 |
| BD | 2 | $63 |
| Pfizer | 2 | $35 |
| Merck | 1 | $17 |
| Chiesi USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,478 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amlodipine Besylate | 16 | $158 |
| Atorvastatin Calcium | 11 | $100 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Browns Mills
- Richard KovachBrowns Mills$300K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.